New Sorafenib Derivatives: Synthesis, Antiproliferative Activity Against Tumour Cell Lines and Antimetabolic Evaluation

Babić, Željka; Crkvenčić, Maja; Rajić, Zrinka; Mikecin, Ana-Matea; Kralj, Marijeta; Balzarini, Jan; Petrova, Mariya; Vanderleyden, Jos; Zorc, Branka

doi:10.3390/molecules17011124

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

New Sorafenib Derivatives: Synthesis, Antiproliferative Activity Against Tumour Cell Lines and Antimetabolic Evaluation

¹,

¹,

¹,

²,

²,

³,

⁴,

⁴ and

^1,*

Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovačića 1, HR-10000 Zagreb, Croatia

Division of Molecular Medicine, Rudjer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

⁴

Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, Bus 2300, B-3001 Heverlee, Belgium

Author to whom correspondence should be addressed.

Molecules 2012, 17(1), 1124-1137; https://doi.org/10.3390/molecules17011124

Received: 26 November 2011 / Revised: 1 January 2012 / Accepted: 5 January 2012 / Published: 23 January 2012

(This article belongs to the Section Medicinal Chemistry)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Sorafenib is a relatively new cytostatic drug approved for the treatment of renal cell and hepatocellular carcinoma. In this report we describe the synthesis of sorafenib derivatives 4a–e which differ from sorafenib in their amide part. A 4-step synthetic pathway includes preparation of 4-chloropyridine-2-carbonyl chloride hydrochloride (1), 4-chloro-pyridine-2-carboxamides 2a–e, 4-(4-aminophenoxy)-pyridine-2-carboxamides 3a–e and the target compounds 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-phenoxy]-pyridine-2-carboxamides 4a–e. All compounds were fully chemically characterized and evaluated for their cytostatic activity against a panel of carcinoma, lymphoma and leukemia tumour cell lines. In addition, their antimetabolic potential was investigated as well. The most prominent antiproliferative activity was obtained for compounds 4a–e (IC₅₀ = 1-4.3 μmol·L⁻¹). Their potency was comparable to the potency of sorafenib, or even better. The compounds inhibited DNA, RNA and protein synthesis to a similar extent and did not discriminate between tumour cell lines and primary fibroblasts in terms of their anti-proliferative activity. View Full-Text

Keywords: sorafenib; amides; cytostatic activity; antimetabolic activity; Caco-2 cells permeability

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License

Share and Cite

MDPI and ACS Style

Babić, Ž.; Crkvenčić, M.; Rajić, Z.; Mikecin, A.-M.; Kralj, M.; Balzarini, J.; Petrova, M.; Vanderleyden, J.; Zorc, B. New Sorafenib Derivatives: Synthesis, Antiproliferative Activity Against Tumour Cell Lines and Antimetabolic Evaluation. Molecules 2012, 17, 1124-1137. https://doi.org/10.3390/molecules17011124

AMA Style

Babić Ž, Crkvenčić M, Rajić Z, Mikecin A-M, Kralj M, Balzarini J, Petrova M, Vanderleyden J, Zorc B. New Sorafenib Derivatives: Synthesis, Antiproliferative Activity Against Tumour Cell Lines and Antimetabolic Evaluation. Molecules. 2012; 17(1):1124-1137. https://doi.org/10.3390/molecules17011124

Chicago/Turabian Style

Babić, Željka, Maja Crkvenčić, Zrinka Rajić, Ana-Matea Mikecin, Marijeta Kralj, Jan Balzarini, Mariya Petrova, Jos Vanderleyden, and Branka Zorc. 2012. "New Sorafenib Derivatives: Synthesis, Antiproliferative Activity Against Tumour Cell Lines and Antimetabolic Evaluation" Molecules 17, no. 1: 1124-1137. https://doi.org/10.3390/molecules17011124

Find Other Styles

Article Metrics

Abstract views Pdf views Html views

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.

Article Menu

New Sorafenib Derivatives: Synthesis, Antiproliferative Activity Against Tumour Cell Lines and Antimetabolic Evaluation

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI